# Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma

> **NCT02270034** · PHASE1 · COMPLETED · sponsor: **Grupo Español de Investigación en Neurooncología** · enrollment: 38 (actual)

## Conditions studied

- Glioblastoma Multiforme (Grade IV) of Cerebellum

## Interventions

- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT02270034
- **Lead sponsor:** Grupo Español de Investigación en Neurooncología
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-13
- **Primary completion:** 2020-10-26
- **Final completion:** 2020-10-26
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02270034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02270034, "Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02270034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*